Marker Therapeutics Inc (MRKR)

[Bio7mm]

Lately I've seen some biotechs like Marina Biotech, Benitec and Arrowhead Research stay above their capital raise prices and continue to move higher with no movement toward the capital raise share price. This hungry environment for development biotechs has changed the old rules where a capital raise would bring the price down to that level. Especially since these results don't incorporate the new class I Mayo antigen.